Allarity Therapeutics, Inc. 8K

Allarity Therapeutics reported Q2 2026 results, strengthened its cash position, completed a Phase 3‑ready stenoparib manufacturing campaign, secured a key U.S. DRP patent and CLIA lab certification, and presented supportive clinical and mechanistic data for stenoparib.

On August 14, 2026, Allarity Therapeutics, Inc. reported its financial results and operational updates for the quarter ended June 30, 2026, highlighting quarter-end cash and restricted cash of $26.9 million, reduced R&D and G&A expenses versus the prior year, and a total comprehensive loss of $3.7 million, while also announcing completion of its Phase 3‑ready stenoparib API manufacturing campaign in July 2026 with no further API manufacturing cash outlays expected, the grant of a key U.S. patent extending exclusivity for the stenoparib DRP companion diagnostic into April 2042, CLIA certification of its in‑house laboratory in Denmark to support DRP testing for U.S. trials, and multiple positive data presentations at AACR 2026 and ESMO Gynaecological Cancers regarding stenoparib’s activity and DRP-guided patient selection in ovarian and colorectal cancers.

Filing Facts

CIK

1860657

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-090183

Alert Tier

6